MX2017004001A - Humanizacion de anticuerpos a base de angulo de interdominio de cadena pesada-cadena ligera (vh-vl). - Google Patents

Humanizacion de anticuerpos a base de angulo de interdominio de cadena pesada-cadena ligera (vh-vl).

Info

Publication number
MX2017004001A
MX2017004001A MX2017004001A MX2017004001A MX2017004001A MX 2017004001 A MX2017004001 A MX 2017004001A MX 2017004001 A MX2017004001 A MX 2017004001A MX 2017004001 A MX2017004001 A MX 2017004001A MX 2017004001 A MX2017004001 A MX 2017004001A
Authority
MX
Mexico
Prior art keywords
antibody
fragments
fragment
variant
variant antibody
Prior art date
Application number
MX2017004001A
Other languages
English (en)
Inventor
Georges Guy
Lipsmeier Florian
Bujotzek Alexander
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2017004001A publication Critical patent/MX2017004001A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21106—Hepsin (3.4.21.106)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente se describe un método para seleccionar uno o más fragmentos Fv de anticuerpo variante derivados de un fragmento Fv de anticuerpo progenitor que comprende las etapas de i) generar una multitud de fragmentos Fv de anticuerpo variante por injerto/transferencia de uno o más residuos determinantes de la especificidad del fragmento Fv de anticuerpo progenitor en un fragmento Fv de anticuerpo aceptor, con lo que cada fragmento Fv de anticuerpo variante de la multitud de fragmentos Fv de anticuerpo variante difiere de los demás fragmentos Fv de anticuerpo variante por al menos un residuo de aminoácido, ii) determinar la orientación VH-VL para el fragmento Fv progenitor y para cada uno de los fragmentos Fv de anticuerpo variante de la multitud de fragmentos Fv de anticuerpo variante con base en una huella digital de secuencia del fragmento Fv de anticuerpo, y iii) seleccionar los fragmentos Fv de anticuerpo variante que tengan la menor diferencia en la orientación VH-VL en comparación con la orientación VH-VL del anticuerpo progenitor y de esta manera seleccionar uno o más fragmentos Fv de anticuerpo variante derivados de un fragmento Fv de anticuerpo progenitor, con lo cual el uno o más fragmentos Fv de anticuerpo variante se unen al mismo antígeno que el fragmento Fv de anticuerpo progenitor.
MX2017004001A 2014-10-24 2015-10-21 Humanizacion de anticuerpos a base de angulo de interdominio de cadena pesada-cadena ligera (vh-vl). MX2017004001A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14190307 2014-10-24
PCT/EP2015/074294 WO2016062734A1 (en) 2014-10-24 2015-10-21 Vh-vl-interdomain angle based antibody humanization

Publications (1)

Publication Number Publication Date
MX2017004001A true MX2017004001A (es) 2017-06-30

Family

ID=51799006

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004001A MX2017004001A (es) 2014-10-24 2015-10-21 Humanizacion de anticuerpos a base de angulo de interdominio de cadena pesada-cadena ligera (vh-vl).

Country Status (12)

Country Link
US (2) US20170204182A1 (es)
EP (1) EP3209684B1 (es)
JP (1) JP6829194B2 (es)
KR (1) KR20170070070A (es)
CN (1) CN107074933B (es)
BR (1) BR112017005451A2 (es)
CA (1) CA2960445A1 (es)
DK (1) DK3209684T3 (es)
ES (1) ES2857553T3 (es)
MX (1) MX2017004001A (es)
RU (1) RU2017115212A (es)
WO (1) WO2016062734A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
RU2766234C2 (ru) 2017-04-04 2022-02-10 Ф. Хоффманн-Ля Рош Аг Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap
CN110945023B (zh) 2017-07-31 2023-08-18 豪夫迈·罗氏有限公司 基于三维结构的人源化方法
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
EP3861025A1 (en) 2018-10-01 2021-08-11 F. Hoffmann-La Roche AG Bispecific antigen binding molecules with trivalent binding to cd40
MA53806A (fr) 2018-10-01 2022-01-05 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène comprenant un clone anti-fap 212
WO2020260326A1 (en) 2019-06-27 2020-12-30 F. Hoffmann-La Roche Ag Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
JP2022543551A (ja) 2019-07-31 2022-10-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｇｐｒｃ５ｄに結合する抗体
WO2021018859A2 (en) 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Antibodies binding to gprc5d
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
EP4408878A1 (en) * 2021-11-04 2024-08-07 Vibrant Pharma Limited Methods for antibody optimization

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6849425B1 (en) * 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
WO2004006955A1 (en) * 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
PT2000481E (pt) * 2003-02-01 2016-06-17 Tanox Inc Anticorpos anti-ige humana de alta afinidade
GB0613209D0 (en) * 2006-07-03 2006-08-09 Ucb Sa Methods
AP2010005354A0 (en) * 2008-01-23 2010-08-31 Acharya Subrat K A humanized high affinity recombinant antibody against hepatitis B surface antigen
GB0914691D0 (en) * 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
IN2012DN02869A (es) * 2009-09-06 2015-07-24 Protab Ltd
US20130108641A1 (en) * 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies

Also Published As

Publication number Publication date
BR112017005451A2 (pt) 2018-01-02
US20200377590A1 (en) 2020-12-03
EP3209684B1 (en) 2020-12-23
WO2016062734A1 (en) 2016-04-28
JP2017531443A (ja) 2017-10-26
CN107074933A (zh) 2017-08-18
US20170204182A1 (en) 2017-07-20
KR20170070070A (ko) 2017-06-21
ES2857553T3 (es) 2021-09-29
CA2960445A1 (en) 2016-04-28
RU2017115212A (ru) 2018-11-26
JP6829194B2 (ja) 2021-02-10
CN107074933B (zh) 2021-03-19
RU2017115212A3 (es) 2019-04-24
DK3209684T3 (da) 2021-02-22
EP3209684A1 (en) 2017-08-30

Similar Documents

Publication Publication Date Title
MX2017004001A (es) Humanizacion de anticuerpos a base de angulo de interdominio de cadena pesada-cadena ligera (vh-vl).
PH12020550214A1 (en) Antibodies specific to cd47 and pd-l1
MX2022009875A (es) Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes.
MX2019008146A (es) Virus alterado.
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
PH12016501212A1 (en) Human anti-il-33 neutralizing monoclonal antibody
MX2022002364A (es) Anticuerpos anti-pd-l1.
EP4303235A3 (en) Lag-3-binding moleculkes and methods of use thereof
AU2016320748A8 (en) Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
MX2019010922A (es) Anticuerpos anti-phf-tau y usos de estos.
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
MX2021003549A (es) Anticuerpos dobles especificos.
WO2019014328A3 (en) AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
WO2018035084A8 (en) Monovalent asymmetric tandem fab bispecific antibodies
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
AR105267A1 (es) Anticuerpos de unión a tau
PE20240365A1 (es) Anticuerpos anti-c5 y metodos de uso
EP4324481A3 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MY175878A (en) Anti-il-17 antibodies, a method for producing and using thereof
MX2019003890A (es) Anticuerpos con union reducida a impurezas de proceso.
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
WO2015013389A3 (en) Anti-galectin-1 (gal1) monoclonal antibodies and fragments thereof for neutralizing gal1
PH12019502298A1 (en) Monoclonal antibody to pd-l1
NZ730519A (en) Peptide microarrays and novel biomarkers for celiac disease
MX2017015927A (es) Fragmentos mutantes de proteina ras.